External beam radiotherapy dose response of prostate cancer

Alan Pollack, Gunar K. Zagars

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

Purpose: To determine the external beam radiotherapy dose response of palpable Stage T1-T4, mostly Nx, patients with adenocarcinoma of the prostate. Methods and Materials: There were 938 men consecutively treated between 1987 and 1995 who had pretreatment prostate specific antigen (PSA) levels. Posttreatment failure was defined as disease recurrence and/or two elevations in PSA on consecutive follow-up visits. The radiotherapy technique consisted of a four-field box with a small four-field reduction after 46 Gy in 844 patients (total dose of 60-70 Gy) or with a six-field conformal boost after 46 Gy in 94 patients (total dose of 74-78 Gy). Neoadjuvant or adjuvant androgen ablation was not used in any patient. Median follow-up was 40 months. Results: The mean and median radiotherapy doses for the entire group were 67.8 ±13.3 Gy (±SEM) and 66 Gy. The mean radiotherapy dose was higher in those who had Stage T3/T4 disease, Gleason scores of 8-10, or pretreatment PSAs of >4 ng/ml. In general, patients with more aggressive pretreatment prognostic features were treated to higher doses; yet, those that relapsed or had a rising PSA were treated to significantly lower doses. Actuarial analyses were facilitated by dividing patients into three dose groups: ≤67, >67-77, and >77 Gy. The actuarial freedom from failure rates at 3 years were 61, 74, and 96% for the low, intermediate, and high dose groups. Stratification of the patients by pretreatment PSA revealed that dose was a significant correlate of freedom from relapse or a rising PSA for those with PSAs >4-10, >10-20, and >20 ng/ml. The only patients in which an improvement in outcome was not related to higher doses were those with a pretreatment PSA ≤4 ng/ml. Dose was significantly associated with freedom from failure for Stage T1/T2 and Stage T3/T4 patients, as well as for those stratified by Gleason score. Multivariate analysis using Cox proportional hazards models showed that dose was on independent and highly significant predictor of relapse or a rising PSA. Conclusion: This retrospective review strongly indicates that radiotherapy dose to the prostate is critical to the cure of prostate cancer, even for favorable patients with pretreatment PSAs of >4-10 ng/ml, Stages T1/T2, or Gleason scores of 2-6. Final confirmation awaits the results of our randomized trial.

Original languageEnglish
Pages (from-to)1011-1018
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume39
Issue number5
DOIs
StatePublished - Dec 1 1997
Externally publishedYes

Fingerprint

radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Prostate-Specific Antigen
dosage
antigens
pretreatment
Neoplasm Grading
Recurrence
Prostate
Actuarial Analysis
Proportional Hazards Models
Androgens
Adenocarcinoma
Multivariate Analysis
stratification
acceleration (physics)
hazards
ablation

Keywords

  • Dose
  • Prostate-specific antigen
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

External beam radiotherapy dose response of prostate cancer. / Pollack, Alan; Zagars, Gunar K.

In: International Journal of Radiation Oncology Biology Physics, Vol. 39, No. 5, 01.12.1997, p. 1011-1018.

Research output: Contribution to journalArticle

@article{c903a0110a2f4119b3fc2adb75c0eae8,
title = "External beam radiotherapy dose response of prostate cancer",
abstract = "Purpose: To determine the external beam radiotherapy dose response of palpable Stage T1-T4, mostly Nx, patients with adenocarcinoma of the prostate. Methods and Materials: There were 938 men consecutively treated between 1987 and 1995 who had pretreatment prostate specific antigen (PSA) levels. Posttreatment failure was defined as disease recurrence and/or two elevations in PSA on consecutive follow-up visits. The radiotherapy technique consisted of a four-field box with a small four-field reduction after 46 Gy in 844 patients (total dose of 60-70 Gy) or with a six-field conformal boost after 46 Gy in 94 patients (total dose of 74-78 Gy). Neoadjuvant or adjuvant androgen ablation was not used in any patient. Median follow-up was 40 months. Results: The mean and median radiotherapy doses for the entire group were 67.8 ±13.3 Gy (±SEM) and 66 Gy. The mean radiotherapy dose was higher in those who had Stage T3/T4 disease, Gleason scores of 8-10, or pretreatment PSAs of >4 ng/ml. In general, patients with more aggressive pretreatment prognostic features were treated to higher doses; yet, those that relapsed or had a rising PSA were treated to significantly lower doses. Actuarial analyses were facilitated by dividing patients into three dose groups: ≤67, >67-77, and >77 Gy. The actuarial freedom from failure rates at 3 years were 61, 74, and 96{\%} for the low, intermediate, and high dose groups. Stratification of the patients by pretreatment PSA revealed that dose was a significant correlate of freedom from relapse or a rising PSA for those with PSAs >4-10, >10-20, and >20 ng/ml. The only patients in which an improvement in outcome was not related to higher doses were those with a pretreatment PSA ≤4 ng/ml. Dose was significantly associated with freedom from failure for Stage T1/T2 and Stage T3/T4 patients, as well as for those stratified by Gleason score. Multivariate analysis using Cox proportional hazards models showed that dose was on independent and highly significant predictor of relapse or a rising PSA. Conclusion: This retrospective review strongly indicates that radiotherapy dose to the prostate is critical to the cure of prostate cancer, even for favorable patients with pretreatment PSAs of >4-10 ng/ml, Stages T1/T2, or Gleason scores of 2-6. Final confirmation awaits the results of our randomized trial.",
keywords = "Dose, Prostate-specific antigen, Radiotherapy",
author = "Alan Pollack and Zagars, {Gunar K.}",
year = "1997",
month = "12",
day = "1",
doi = "10.1016/S0360-3016(97)00508-7",
language = "English",
volume = "39",
pages = "1011--1018",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - External beam radiotherapy dose response of prostate cancer

AU - Pollack, Alan

AU - Zagars, Gunar K.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Purpose: To determine the external beam radiotherapy dose response of palpable Stage T1-T4, mostly Nx, patients with adenocarcinoma of the prostate. Methods and Materials: There were 938 men consecutively treated between 1987 and 1995 who had pretreatment prostate specific antigen (PSA) levels. Posttreatment failure was defined as disease recurrence and/or two elevations in PSA on consecutive follow-up visits. The radiotherapy technique consisted of a four-field box with a small four-field reduction after 46 Gy in 844 patients (total dose of 60-70 Gy) or with a six-field conformal boost after 46 Gy in 94 patients (total dose of 74-78 Gy). Neoadjuvant or adjuvant androgen ablation was not used in any patient. Median follow-up was 40 months. Results: The mean and median radiotherapy doses for the entire group were 67.8 ±13.3 Gy (±SEM) and 66 Gy. The mean radiotherapy dose was higher in those who had Stage T3/T4 disease, Gleason scores of 8-10, or pretreatment PSAs of >4 ng/ml. In general, patients with more aggressive pretreatment prognostic features were treated to higher doses; yet, those that relapsed or had a rising PSA were treated to significantly lower doses. Actuarial analyses were facilitated by dividing patients into three dose groups: ≤67, >67-77, and >77 Gy. The actuarial freedom from failure rates at 3 years were 61, 74, and 96% for the low, intermediate, and high dose groups. Stratification of the patients by pretreatment PSA revealed that dose was a significant correlate of freedom from relapse or a rising PSA for those with PSAs >4-10, >10-20, and >20 ng/ml. The only patients in which an improvement in outcome was not related to higher doses were those with a pretreatment PSA ≤4 ng/ml. Dose was significantly associated with freedom from failure for Stage T1/T2 and Stage T3/T4 patients, as well as for those stratified by Gleason score. Multivariate analysis using Cox proportional hazards models showed that dose was on independent and highly significant predictor of relapse or a rising PSA. Conclusion: This retrospective review strongly indicates that radiotherapy dose to the prostate is critical to the cure of prostate cancer, even for favorable patients with pretreatment PSAs of >4-10 ng/ml, Stages T1/T2, or Gleason scores of 2-6. Final confirmation awaits the results of our randomized trial.

AB - Purpose: To determine the external beam radiotherapy dose response of palpable Stage T1-T4, mostly Nx, patients with adenocarcinoma of the prostate. Methods and Materials: There were 938 men consecutively treated between 1987 and 1995 who had pretreatment prostate specific antigen (PSA) levels. Posttreatment failure was defined as disease recurrence and/or two elevations in PSA on consecutive follow-up visits. The radiotherapy technique consisted of a four-field box with a small four-field reduction after 46 Gy in 844 patients (total dose of 60-70 Gy) or with a six-field conformal boost after 46 Gy in 94 patients (total dose of 74-78 Gy). Neoadjuvant or adjuvant androgen ablation was not used in any patient. Median follow-up was 40 months. Results: The mean and median radiotherapy doses for the entire group were 67.8 ±13.3 Gy (±SEM) and 66 Gy. The mean radiotherapy dose was higher in those who had Stage T3/T4 disease, Gleason scores of 8-10, or pretreatment PSAs of >4 ng/ml. In general, patients with more aggressive pretreatment prognostic features were treated to higher doses; yet, those that relapsed or had a rising PSA were treated to significantly lower doses. Actuarial analyses were facilitated by dividing patients into three dose groups: ≤67, >67-77, and >77 Gy. The actuarial freedom from failure rates at 3 years were 61, 74, and 96% for the low, intermediate, and high dose groups. Stratification of the patients by pretreatment PSA revealed that dose was a significant correlate of freedom from relapse or a rising PSA for those with PSAs >4-10, >10-20, and >20 ng/ml. The only patients in which an improvement in outcome was not related to higher doses were those with a pretreatment PSA ≤4 ng/ml. Dose was significantly associated with freedom from failure for Stage T1/T2 and Stage T3/T4 patients, as well as for those stratified by Gleason score. Multivariate analysis using Cox proportional hazards models showed that dose was on independent and highly significant predictor of relapse or a rising PSA. Conclusion: This retrospective review strongly indicates that radiotherapy dose to the prostate is critical to the cure of prostate cancer, even for favorable patients with pretreatment PSAs of >4-10 ng/ml, Stages T1/T2, or Gleason scores of 2-6. Final confirmation awaits the results of our randomized trial.

KW - Dose

KW - Prostate-specific antigen

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0030661678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030661678&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(97)00508-7

DO - 10.1016/S0360-3016(97)00508-7

M3 - Article

VL - 39

SP - 1011

EP - 1018

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -